• Fortrea Holdings Inc., a contract research organization spun off from Labcorp in 2023, has recently reported that its sales have declined by an average 2.9% each year over the past four years, alongside returns on capital that remain below zero.
• This combination of contracting revenue and ineffective investment decisions suggests earlier profit pools are shrinking and raises fresh questions about the company’s ability to execute its growth plans.
• Against this backdrop of multi‑year sales decline and negative returns on capital, we’ll now examine how these headwinds affect Fortrea’s investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Fortrea Holdings Investment Narrative Recap

To own Fortrea, you need to believe that demand for outsourced clinical trials and its technology investments can eventually offset today’s shrinking sales base and negative returns on capital. The recent disclosure of a 2.9% annual revenue decline over four years directly challenges near term confidence in a revenue inflection, and it sharpens the biggest current risk: that new leadership and cost savings fail to stabilize performance before key customers or creditors lose patience.

Against this backdrop, the launch of Fortrea Intelligent Technology (FIT) in April 2026 stands out. FIT is meant to modernize trial execution with AI enabled tools and real time data, which ties closely to the core catalyst that Fortrea can improve efficiency and differentiate its services. With revenues under pressure and returns on capital still negative, the effectiveness and adoption of FIT will be a practical test of whether technology can help restore economic discipline.

Yet beneath these technology promises, investors should be aware of the concentration risk in Fortrea’s largest customers and how...

Fortrea Holdings’ narrative projects $2.7 billion in revenue and $388.5 million in earnings by 2028. This implies a 0.1% yearly revenue decline and an earnings increase of about $1.4 billion from -$1.0 billion today.

Uncover how Fortrea Holdings' forecasts yield a $14.44 fair value, a 19% upside to its current price.

Exploring Other Perspectives

While consensus once assumed modest growth off about US$2.6 billion of revenue, the most pessimistic analysts already flagged that slower biotech wins could compound shrinking sales and see margins stay under pressure, so this latest data may push their already cautious view even further and is a reminder that you should compare several different scenarios before deciding what you believe about Fortrea’s future.

Explore 2 other fair value estimates on Fortrea Holdings - why the stock might be worth as much as 78% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Fortrea Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Fortrea Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fortrea Holdings' overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.